Projects

Deputy Scientific Director of IEPT CEM SAS, the member of the Department of tissue cultures and biochemical engineering
Ing. Zuzana Brnoliaková, PhD.

National

Finished
  • The use of mass spectrometry for comparative study of different rats strains glycoprofiles within metabolic disturbances intervention
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2023
  • Innovative approaches in toxicology of ageing
    Program: SRDA
    Duration: 1. 7. 2019 – 30. 6. 2023
  • The study of structural changes of complex glycoconjugates in the proces of inherited metabolic and civilization diseases
    Program:
    Duration: 1. 3. 2021 – 30. 6. 2023
  • Effect of fructose diet in experimental models of metabolic syndrome and in healthy subjects: proposal of effective pharmacological treatment
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2022
  • Risk factors of cardiovascular and cerebrovascular diseases and pharmacological possibilities of their influence
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • Centre of excellence for glycomics
    Program: EU Structural Funds Research & Development
    Duration: 1. 10. 2010 – 31. 10. 2013
  • Could the diabetic cataract prevention be achieved by substituted pyridoindoles with their antioxidant and aldose reductase inhibitory potential? Study on in vitro cultivated eye lenses from rats
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • Substituted pyridoindoles as antioxidants and aldose reductase inhibitors in multitarget treatment of diabetic complications: a preclinical study
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Developmental Origin of Metabolic Syndrome:Hypertension, Diabetes and Dyslipidemia
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Ischaemia and reperfusion in experimental diabetes type 2 and possibilities of pharmacological management
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
  • Carboxymethylated pyridoindoles as inhibitors of aldose reductase with antioxidant activity: preclinical implicators for pharmacological prevention of diabetic complications
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
Employees